Collectively, the BC+sST2 composite hydrogel demonstrates superior efficacy over BC alone in mitigating early inflammatory responses and subsequent heterotopic ossification progression, highlighting the therapeutic potential of targeting IL-33 signaling in HO intervention. Here, IL33 is linked to breast cancer.